What Are Disease-Modifying Therapies for Type 1 Diabetes?

Researchers are developing treatments designed to preserve or restore the pancreas's ability to produce insulin by protecting beta cells from immune attack. These therapies aim to change the course of Type 1 diabetes at any stage of the disease.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

Disease-modifying therapies target the root cause of Type 1 diabetes: the immune system attacking insulin-producing beta cells in the pancreas
The goal is to prevent, halt, or reverse beta cell loss—not simply manage blood sugar levels
These therapies could potentially be used at any stage of Type 1 diabetes, from early detection through established disease
Approaches include treatments that either modify immune function or directly protect and restore beta cells
This represents a shift from insulin replacement toward changing the disease itself

Understanding What Goes Wrong in Type 1 Diabetes

In a healthy pancreas, beta cells quietly do their job: producing insulin, the hormone that allows glucose to enter cells and provide energy. In Type 1 diabetes, the immune system mistakenly treats these beta cells as a threat and attacks them, destroying the body's ability to make insulin. This is why people with Type 1 diabetes need to inject or deliver insulin to survive.

The damage happens at the cellular level, but the impact is life-changing. Without a way to stop or reverse this immune attack, blood glucose levels climb dangerously high, and insulin replacement becomes necessary for survival.

What Disease-Modifying Therapies Aim to Do

Disease-modifying therapies represent a different approach to Type 1 diabetes. Instead of only replacing the insulin the body can no longer make, these treatments are designed to preserve, halt, or even restore the pancreas's own ability to produce insulin.

By targeting either the immune cells that attack beta cells or the beta cells themselves, these therapies aim to change the underlying disease process rather than simply manage its symptoms. If successful, they could fundamentally alter the course of Type 1 diabetes.

A Potential Option at Any Stage

What makes disease-modifying therapies particularly promising is their potential applicability across the full spectrum of Type 1 diabetes. Researchers envision these treatments could be used whether someone has recently been diagnosed, is in the early stages of the disease, or has lived with Type 1 diabetes for years.

This broad scope reflects the ambition of the research effort: to offer new options to every person affected by Type 1 diabetes, regardless of when they develop the condition.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.